Source comparison
CJC-1295 vs CJC-1295 No DAC — Research Peptide Comparison
A 2006 study published in the Journal of Clinical Endocrinology & Metabolism found that adding Drug Affinity Complex (DAC) to Modified GRF 1-29 extended the peptide's half-life from approximately 30 minutes to 6–8 days. Fundamentally altering its pharmacokinet
This comparison does not assign a generated winner or score.
- A 2006 study published in the Journal of Clinical Endocrinology & Metabolism found that adding Drug Affinity Complex (DAC) to Modified GRF 1-29 extended the peptide's half-life from approximately 30 minutes to 6–8 days. Fundamentally altering its pharmacokinetics and research applications. That single modification created two distinct peptides with identical amino acid cores but profoundly different release patterns, dosing protocols, and experimental use cases.
- We've worked with research teams across academic and private institutions who initially assumed these peptides were interchangeable variants. They aren't. The CJC-1295 vs CJC-1295 no DAC comparison comes down to duration versus pulsatility. One sustains growth hormone (GH) elevation for days; the other mimics the body's natural secretory bursts over hours.
- What's the difference between CJC-1295 with DAC and CJC-1295 no DAC?
- CJC-1295 with DAC is a growth hormone-releasing hormone (GHRH) analogue that binds to serum albumin, extending its half-life to approximately 6–8 days and producing sustained GH elevation. CJC-1295 no DAC. Also called Modified GRF 1-29 or Mod GRF. Lacks the DAC component, resulting in a half-life of 30 minutes and pulsatile GH release that mirrors natural physiological patterns. The choice depends on whether the research protocol requires sustained baseline elevation or preservation of endogenous pulsatility.
- The naming confusion stems from early research nomenclature. 'CJC-1295' originally referred to the DAC-conjugated version; 'CJC-1295 no DAC' was retrospectively applied to Modified GRF 1-29 after researchers began comparing the two. This article covers the pharmacokinetic mechanisms that differentiate them, the dosing protocols that reflect those differences, and the specific research contexts where one peptide type outperforms the other.